Physicians' Academy for Cardiovascular Education

Understanding BET inhibition as a novel pathway for cardiovascular risk modulation

10' education - Aug. 28, 2016 - ESC 2016, Rome - Jorge Plutzky, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA - Recorded at PACE-CME symposium at ESC 2016

This lecture was part of a CME accredited symposium: 'A novel approach for high CV risk patients with diabetes: The potential of epigenetics' held at ESC 2016 in Rome

Video navigation menu

  • Concept of coordinated programs in cardiometabolic states by key proximal transcription factors 00:40
  • Epigenetics as a way of regulating these programs above the level of the DNA 03:40
  • The role of epigenetics in diabetes 06:53
  • Current issues in epigenetics/BETs: Super enhancers 09:30
  • Endothelial effects of BET inhibition 10:47
  • Association of BRD4 with many pro-inflammatory, pro-atherosclerotic target genes 14:28
  • Apabetalone reduces atheroma in aorta of apo E-/- mice 15:52

Educational information

The educational objectives of this symposium were:

CME accreditation

This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).


Jorge Plutzky, M.D. is the Director of the Vascular Disease Prevention Program, which includes the Lipid/Prevention Clinic, at Brigham and Women’s Hospital (BWH), and is on the faculty of Harvard Medical School


Supported by an unrestricted educational grant from Resverlogix

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends:

Tc5IDE4Ljc5Mjc2NywtMTMuMDE2MzYgMzEuODA5MTMyLC0xNy4zNjgwMiAxMy4wMTYzNTYsLTQuMzUxNjcgMjYuMDMyNzIyLC03LjIzOTggNDAuNDczOTc4LC03LjIzOTggaCA3LjIzOTggdiA0MC40NzQgTCAxOTguMzE1NzYsODYuMTk0MjQxIDExNS45NDMwNCwxMy45ODgwNjIgWiIKICAgICBjbGFzcz0icGF0aDEiIC8+Cjwvc3ZnPgo=" alt="Share" onclick="share(event);">